Review of catumaxomab in the treatment of malignant ascites

Cancer Management and Research

Volumn 2, Issue 1, 2010, Pages 283-286

  Sebastian, Martin ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Ascites; Catumaxomab; Epithelial cell adhesion molecule

Indexed keywords

CATUMAXOMAB; CD3 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; T LYMPHOCYTE ANTIGEN;

ABDOMINAL PAIN; ACCESSORY CELL; ARTICLE; ASCITES; BINDING AFFINITY; CANCER SURVIVAL; CELL KILLING; CHILL; DENDRITIC CELL; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG SPECIFICITY; EUROPE; FEVER; HISTOCOMPATIBILITY COMPLEX; HUMAN; ILEUS; LYMPHOCYTOPENIA; MACROPHAGE; MALIGNANT ASCITES; MESOTHELIUM; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NAUSEA; PAIN; PARACENTESIS; PERITONEUM VEIN SHUNT; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR CELL; VOMITING;

EID: 79251472492     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/CMR.S14115     Document Type: Article

References (23)

1. Tamsma J. The pathogenesis of malignant ascites. Cancer Treat Res. 2007;134:109-118.
2. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: A retrospective study. Ann Oncol. 2007;18(5): 945-949.
3. El-Shami K, Elsaid A, El-Kerm Y. Open-label safety and effcacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol. 2007;25 Suppl 18:9043.
4. Schmitt M, Schmitt A, Reinhardt P, et al. Opsonization with a trifunc-tional bispecifc (alphaCD3 x alphaEpCAM) antibody results in effcient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol. 2004;25(4):841-848.
5. Ruf P, Gires O, Jager M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specifc antibody HO-3: Implications for trifunctional antibody immunotherapy of cancer. Br J Cancer. 2007; 97(3):315-321.
6. Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecifc antibody results in effcient tumor cell killing. J Immunol. 1999;163(3): 1246-1252.
7. Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecifc antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83(2):261-266.
8. Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecifc antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem. 2001;49(7):911-917.
9. Litvinov S V, Velders M P, Bakker HA, Fleuren GJ, Warnaar SO. Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol. 1994;125(2):437-446.
10. Balzar M, Winter MJ, de Boer CJ, Litvinov S V. The biology of the 17-1A antigen (Ep-CAM). J Mol Med. 1999;77(10):699-712.
11. Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 2004;64(16):5818-5824.
12. Went P, Vasei M, Bubendorf L, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006;94(1):128-135.
13. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122-128.
14. Schmidt M, Hasenclever D, Schaeffer M, et al. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res. 2008;14(18):5849-5855.
15. Schmidt M, Petry IB, Bohm D, et al. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Breast Cancer Res Treat. 2010 Mar 30. [Epub ahead of print].
16. Litvinov S V, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol. 1997;139(5):1337-1348.
17. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene. 2004;23(34):5748-5758.
18. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11(2):162-171.
19. Lindhofer H, Schoberth A, Pelster D, Hess J, Herold J, Jager M. Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: Results from a pivotal phase II/III study. J Clin Oncol. 2009;27 Suppl 15:3014.
20. Hirschhaeuser F, Walenta S, Mueller-Klieser W. Effcacy of catumax-omab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol Immunother. 2010;59(11):1675-1684.
21. Heiss MM, Strohlein MA, Jager M, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 2005;117(3): 435-443.
22. Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Clin Cancer Res. 2007;13(13):3899-3905.
23. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209-2221.